Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.75, $0.03 better than the analyst estimate of $0.72. Revenue for the quarter came in at $767.7 million versus the consensus estimate of $759.54 million.

GUIDANCE:

Edwards Lifesciences sees Q1 2017 EPS of $0.79-$0.89, versus the consensus of $0.81. Edwards Lifesciences sees Q1 2017 revenue of $760-800 million, versus the consensus of $778.1 million.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.